Literature DB >> 9201229

Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

M A Vodicka1, W C Goh, L I Wu, M E Rogel, S R Bartz, V L Schweickart, C J Raport, M Emerman.   

Abstract

CCR5 and CXCR4 are the two major coreceptors that have been identified for human immunodeficiency virus (HIV) entry. We have modified several beta-galactosidase-based HIV indicator cell lines to express CCR5 and/or CXCR4. Using these new reagents, we have been able to detect all primary isolates tested using one or both of these cell lines. However, there is large variation in the absolute viral infectivity among primary strains. Furthermore, all HIV strains are capable of causing syncytia in the indicator cells when the coreceptor is present regardless of whether they had previously been characterized as "syncytia-inducing" or "non-syncytium-inducing."

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201229     DOI: 10.1006/viro.1997.8606

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  116 in total

1.  Bone marrow CD34(+) cells and megakaryoblasts secrete beta-chemokines that block infection of hematopoietic cells by M-tropic R5 HIV.

Authors:  M Majka; T Rozmyslowicz; B Lee; S L Murphy; Z Pietrzkowski; G N Gaulton; L Silberstein; M Z Ratajczak
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo.

Authors:  S M Kao; E D Miller; L Su
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

4.  Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.

Authors:  M Haddrick; C R Brown; R Plishka; A Buckler-White; V M Hirsch; H Ginsberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Authors:  T R Fouts; R Tuskan; K Godfrey; M Reitz; D Hone; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Authors:  Natallia Dziuba; Monique R Ferguson; William A O'Brien; Anthony Sanchez; Andrew J Prussia; Natalie J McDonald; Brian M Friedrich; Guangyu Li; Michael W Shaw; Jinsong Sheng; Thomas W Hodge; Donald H Rubin; James L Murray
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

8.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

9.  Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.

Authors:  Eric G Meissner; Karen M Duus; Feng Gao; Xiao-Fang Yu; Lishan Su
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

10.  Exploiting drug repositioning for discovery of a novel HIV combination therapy.

Authors:  Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.